Does the Galleri (GRAIL) multi‑cancer early detection blood test detect peritoneal cancer?

Does Galleri (GRAIL) Detect Peritoneal Cancer?

Yes, the Galleri MCED test can detect peritoneal cancer, but with significant limitations—it detected cancer signals in only 0.91% of over 111,000 tested individuals, with particularly low sensitivity for early-stage disease (under 30% for Stage I-II cancers), though when cancer is detected, the test correctly identifies the anatomical origin in approximately 87% of cases 1.

Understanding the Test's Capabilities

The Galleri test analyzes methylation patterns in cell-free DNA to detect cancer signals and predict the cancer signal origin (CSO). In real-world implementation across 111,080 individuals:

• Overall detection rate: 0.91% (1,011 positive results)
• Confirmed cancers: 258 invasive cancers spanning 32 different cancer types were diagnosed among those with positive results
• Anatomical accuracy: 87% correct CSO prediction when cancer was confirmed 1

Critical Limitations for Peritoneal Cancer Detection

Sensitivity Issues

The test faces substantial challenges detecting peritoneal malignancies:

• Early-stage sensitivity is poor: Less than 30% for Stage I-II tumors, and under 20% for Stage I disease alone 2, 3
• Small tumor burden problem: Peritoneal metastases often present as small deposits (<5-7 mm), which fall below the test's detection threshold 4
• Biological constraints: When tumors are ≤10-15 mm in diameter, the mutant allele fraction is approximately 0.01%, meaning standard blood volumes may not contain sufficient tumor DNA for reliable detection 2

Comparison to Standard Imaging

Traditional imaging modalities remain superior for peritoneal disease:

• CT imaging: While CT has low sensitivity (28-51%) for peritoneal metastases, it maintains high specificity (97-99%) 5
• Laparoscopy: Remains the gold standard with 85% sensitivity and 100% specificity for detecting peritoneal metastases 6, 7
• MRI and PET-CT: Both have documented limitations detecting small peritoneal deposits (<5-7 mm) 4, 7, 4

Clinical Context and Practical Implications

When the Test May Be Useful

The Galleri test showed promise in real-world settings for detecting various cancers:

• In one tertiary center study, 73% of positive results (11/15 evaluated patients) yielded confirmed cancer diagnoses 8
• The test detected cancers lacking USPSTF-recommended screening, including ovarian cancer (which can present with peritoneal involvement) 9
• Median time from positive result to cancer diagnosis was 39.5 days 1

Critical Caveats

Common pitfalls to avoid:

1. False reassurance: A negative Galleri test does NOT rule out peritoneal cancer, especially early-stage or small-volume disease
2. Histology matters: The test performs poorly with mucinous adenocarcinomas and low-grade tumors—common in peritoneal malignancies 4
3. Cost-benefit uncertainty: With 99.5% specificity but low sensitivity, the test generates false positives requiring expensive workups 2, 3

Appropriate Clinical Use

For suspected peritoneal cancer, follow established guidelines:

• Primary staging: Use contrast-enhanced CT of chest/abdomen/pelvis as initial imaging 10, 4, 6
• Definitive evaluation: Proceed to diagnostic laparoscopy with peritoneal washings for cytology in high-risk cases (T3/T4 disease, poorly cohesive tumors) 6, 7
• Ovarian cancer surveillance: CT remains the modality of choice for detecting peritoneal recurrence, with sensitivity 58-84% 4

Bottom Line for Clinical Practice

The Galleri test should not replace standard diagnostic pathways for peritoneal cancer evaluation. Its role is limited to opportunistic detection in asymptomatic screening populations, not diagnostic workup of suspected peritoneal malignancy. When peritoneal cancer is a clinical concern based on symptoms, imaging findings, or tumor markers (CA-125, CEA), proceed directly to contrast-enhanced CT and consider laparoscopy—do not rely on MCED testing to guide management decisions.

The test's high specificity (>98%) means positive results warrant thorough investigation, but its low sensitivity for early-stage disease means negative results provide minimal clinical reassurance for peritoneal malignancies 1, 3.